Agenus Says Cancer Therapy Evaluation Program Is Accepting LOIs To Conduct Clinical Studies Using Botensilimab, Which Is Being Developed By CTEP As An Anticancer Agent In Collaboration With Company
Portfolio Pulse from Benzinga Newsdesk
Agenus Inc. announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) for clinical studies using botensilimab, an anticancer agent developed in collaboration with Agenus. CTEP will also consider supplying botensilimab for nonclinical studies.
June 27, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agenus Inc. announced that CTEP is accepting LOIs for clinical studies using botensilimab, an anticancer agent developed in collaboration with Agenus. This could lead to increased interest and potential future revenue from successful studies.
The acceptance of LOIs by CTEP for clinical studies using botensilimab indicates progress in the development of this anticancer agent. Successful studies could lead to increased interest in Agenus and potential future revenue, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100